



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

| | | |
|---------------------------------------------------------------------------------------------|------------------------|-------------------|
| TRANSMITTAL FORM (to be used for all correspondence after initial filing) | Application Number | 10/677,551 |
| | Filing Date | October 2, 2003 |
| | First Named Inventor | Barbachyn et al. |
| | Art Unit | 1614 |
| | Examiner Name | not yet available |
| Total Number of Pages in This Submission | Attorney Docket Number | 01337.US1 |

ENCLOSURES (Check all that apply)

| | | |
|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form | <input type="checkbox"/> Drawing(s) | <input type="checkbox"/> After Allowance communication to Group |
| <input type="checkbox"/> Fee Attached | <input type="checkbox"/> Licensing-related Papers | <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences |
| <input type="checkbox"/> Amendment/Reply | <input type="checkbox"/> Petition | <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) |
| <input type="checkbox"/> After Final | <input type="checkbox"/> Petition to Convert to a Provisional Application | <input type="checkbox"/> Proprietary Information |
| <input type="checkbox"/> Affidavits/declaration(s) | <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address | <input type="checkbox"/> Status Letter |
| <input type="checkbox"/> Extension of Time Request | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below): |
| <input type="checkbox"/> Express Abandonment Request | <input type="checkbox"/> Request for Refund | A return-receipt postcard is enclosed. Search Report and references |
| <input checked="" type="checkbox"/> Information Disclosure Statement | <input type="checkbox"/> CD, Number of CD(s) _____ | |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | Remarks | |
| <input type="checkbox"/> Response to Missing Parts/Incomplete Application | | |
| <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | | |

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | |
|-------------------------|--------------------------------------------------------|
| Firm or Individual name | Pharmacia & Upjohn Company, John H. Engelmann (28,075) |
| Signature | John H. Engelmann |
| Date | APRIL 9, 2004 |

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

| | | | |
|-----------------------|----------------|------|---------------|
| Typed or printed name | Julie K. Lyons | | |
| Signature | Julie K. Lyons | Date | April 9, 2004 |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

| | | | | | | | |
|------------------------------------------------------------------------------------------|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|------------------|-------|------------------|----------------------------|
| LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i> | | | | Atty. Docket No. | | Serial No. | |
| | | | | 01337.US1 | | 10/677,551 | |
| | | | | Applicant | | Barbachyn et al. | |
| | | | | Filing Date | | 1614 | |
| U.S. PATENT DOCUMENTS | | | | | | | |
| Examiner Initial | | Document Number | Date | Name | Class | Subclass | Filing Date If Appropriate |
| | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | |
| | | Document Number | Date | Country | Class | Subclass | Translation |
| | | | | | | | Yes No |
| | | | | | | | |
| OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | |
| | AA | H.-J. Boehm, et al., J. Med. Chem., (2000), 43, 2664-2674 | | | | | |
| | AB | D. K. Chen, et al., N. Engl. J. Med., (1999), 341(4), 233-239 | | | | | |
| | AC | I. Chopra et al., JAMA, (1996), 275(5), 401-403 | | | | | |
| | AD | Database Chemcats Online, Chemical Abstracts Service, May 2003, XP002266425 | | | | | |
| | AE | U. Gerlach, "Synthesis of Tricyclic Cyano-Substituted Tetrahydroquinolines by Radical Decyanation of Geminal Dinitriles", Tetrahedron Letters, 36(29), (1995), 5159-5162, XP004027630 | | | | | |
| | AF | D. M. Gleave et al: "Synthesis and Antibacterial activity of [6,5,5] and [6,6,5] Tricyclic Fused Oxazolidinones", Bioorganic & Medicinal Chemistry Letters, 8(10), May 1998. 1231-1236, XP004137053 | | | | | |
| | AG | O. K. Kim, et al., Exp. Opin. Ther. Patents (1998), 8(8), 959-969 | | | | | |
| | AH | P. Kotilainen, et al., J. Infect. Dis., (1990), 161, 41-44 | | | | | |
| | AI | A. Maxwell, Trends in Microbiology, (1997), 5(3), 102-109 | | | | | |
| | AJ | A. Maxwell, Mol. Microbiol., (1993), 9(4), 681-686 | | | | | |
| | AK | W. H. N. Nijhuis et al: "A Novel two-step Synthesis of Hexahydropyrazino [1,2-Alpha]-quinolines", Synthesis, Vol. 7, (1987), 641-645, XP002266422 | | | | | |
| | AL | Walter H. N. Nijhuis, et al: "Stereochemical Aspects of the tert-Amino effect", J. Org. Chem., 54(1), 1989, 209-16, XP002266423 | | | | | |
| | AM | L.L. Silver and A. K. Bostian, Antimicrob. Agents and Chemother., Mar. 1993, 37(3), 377-383 | | | | | |
| | AN | M. Trucksis, et al., Ann. Intern. Med. (1991), 114(5), 424-426 | | | | | |
| | AO | Willem Verboom, et al: "tert-Amino effect in Heterocyclic Synthesis", Journal of Organic Chemistry, (1984), 49(2), 269-276, XP002266421 | | | | | |
| Examiner | | Date Considered | | | | | |